Published: November 2023
On 31 October 2023, United Therapeutics announced the enrolment of first patient in the registration-phase TETON PPF study. The aim of the study is to evaluate nebulized Tyvaso® (treprostinil) Inhalation Solution in 698 adult patients suffering from progressive pulmonary fibrosis (PPF).
The 52-week study aims to evaluate the impact of nebulized Tyvaso on a key prognostic indicator for PPF known as forced vital capacity (FVC). PPF is a progressive form of interstitial lung disease (ILD) characterized by the loss of the ability of the lungs to transfer oxygen into the blood, ultimately resulting in respiratory failure and death.
Nebulized Tyvaso has been approved by the Food and Drug Administration (FDA) to treat both pulmonary arterial hypertension and pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD).
According to Roots Analysis, the Idiopathic Pulmonary Fibrosis Market is anticipated to grow at a stable rate during the forecast period.
For detailed insights about this domain, check out our report on Idiopathic Pulmonary Fibrosis Market or email firstname.lastname@example.org
You may also be interested in the following titles:
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES